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Capsule summary: Severe lower respiratory illnesses (sLRI) during infancy increase the risk of 25 
asthma. The immunomodulator BronchVaxom can increase the time to the first sLRI and reduce 26 
the cumulative burden of sLRI in “at risk” infants.  27 
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Severe lower respiratory illnesses (sLRI) during infancy, i.e. those associated with fever (>38°C) 29 
and/or wheeze, increase the likelihood of subsequent asthma in at-risk subjects1-5. Moreover, time-30 
to-first-sLRI after birth appears significantly reduced in children who develop persistent wheeze5, 31 
suggesting that early infancy may be a period of particularly high vulnerability to the 32 
“asthmatogenic” effects of these infections. Significant interest exists in primary prevention of 33 
asthma and we have previously postulated that this may be achievable by protection against sLRI 34 
during infancy6. However, progress in testing this hypothesis has been limited by the availability of 35 
appropriate therapeutics which are approved for use in this age group. In this regard, the 36 
immunomodulator, OM85 (BronchoVaxom), has been used in Europe to prevent recurrent upper 37 
respiratory infections (URI) in children7 and to reduce the frequency and severity of wheeze 38 
episodes in asthmatic children8. OM85 is a lyophilized extract derived from a mixture of bacterial 39 
respiratory pathogens containing multiple TLR-like ligands, with a long history of safe use in 40 
children. However, it has not been tested previously in the specific context of sLRI prevention in at-41 
risk infants. 42 
We accordingly conducted a randomized clinical trial (BV2012/15, ACTRN12612000518864) 43 
where at-risk infants, by virtue of a parental history of asthma and allergies, were randomized to 44 
OM85 (3.5mg) or identical placebo for the first ten days of April through August; one month before 45 
and during the months of the winter viral seasons in Brisbane, Australia. Infants were 3-9 months of 46 
age when recruited, treated for their first two winter seasons and followed off treatment for a third 47 
year. The primary outcome variable was the frequency of sLRI over the first two winters of the 48 
child’s life (see Supplemental data for clinical definitions). An a priori decision was taken to 49 
complete all secondary analyses for which data were available. All analyses were performed as 50 
intention-to-treat. All children who received at least one dose of study treatment were included in 51 
the safety analyses.  As no previous study had used OM85 in primary prevention of sLRI, we used 52 
the data published by Razi et al.8 showing a 30-40% reduction in wheeze episodes (OM85 53 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT3.57±1.61, placebo 5.75±2.71) in asthmatic children to determine sample size, which showed that 54 
26 children per group would be required to give 80% power (α=0.05) to detect a 38% difference in 55 
sLRI between the groups. We therefore aimed to recruit 30 children per group. Those who 56 
withdrew or dropped out were not replaced, primarily due to resource limitations.  57 
Fifty nine children, aged 5.8±1.9 months were recruited and randomized; 29 to OM85 and 30 to 58 
placebo. There were no differences in demographic characteristics (Supplemental Table 1). One 59 
child from each group withdrew before taking any study medication. Twenty five children 60 
randomized to OM85 had evaluable data at the end of the first winter, 24 at the end of the second 61 
winters and 23 completed the study. More children in the placebo group were lost to follow-up. 62 
Evaluable data were available at the end of the first winter for 27 children, for 22 children at the end 63 
of the second winter and 18 finished the study.   64 
There was no significant difference in the frequency of sLRI over the first two winters between the 65 
groups. Within the OM85 group 17/24 (70.8%) recorded 37 sLRI [median 1.0 (25%-75% 0.0, 2.0)] 66 
and 14/22 (63.6%) recorded 47 sLRI [1.0 (0.0, 4.0)] in the placebo group (p=0.84 Mann-Whitney). 67 
The time to the first sLRI was significantly longer for children receiving OM85 than for those 68 
receiving placebo [median 442.0 (25%, 75% >853.0, 124.0) days vs median 85.0 (25%, 75% 386.0, 69 
54.0) days, p=0.006 Kaplan-Meier survival analysis with Gehan-Breslow test] (Figure 1A). In this 70 
analysis, children who did not experience a sLRI during the study were censored on the date that 71 
they left the study (withdrew or competed). While there was a tendency for a reduction in the 72 
number of children who had any LRI, the number of LRI per child and the time to first LRI, there 73 
were no statistically significant differences between groups (Supplemental data, Supplemental 74 
Tables 2 &3). 75 
OM85 appeared to be more effective at preventing sLRI in the first winter. Fewer children in the 76 
OM85 group had a sLRI than those in the placebo group [6/25 (24.0%) vs 14/27 (51.9%), p=0.05 77 
Fisher Exact). Similarly, children receiving OM85 had fewer sLRI [7 infections, median 0.0 (0.0, 78 
0.75)] than those in the placebo group [18 infections, median 1.0 (0.0, 1.0)] but this did not reach 79 
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statistical significance (p=0.052). For those children who did have sLRI, there was no difference in 80 
duration for those in the active and control groups [10.3 (8.3, 25.8) days vs 20.0 (7.0, 23.3) days, 81 
p=0.61]. 82 
There did not appear to be any carry over protection for the rest of the first year of the study once 83 
children stopped taking OM85 [OM85 on 6/25 (24.0%), off 11/25 (44.4%), placebo on 12/27 84 
(44.4%), off 4/27 (14.8%), p=0.046 Chi Square]. A similar pattern was seen for the number of sLRI 85 
during the first study year [OM85 on: median 0.00 (0.00, 0.75); off: 0.50 (0.00, 1.00); placebo on: 86 
0.00 (0.00, 1.00); off: 0.00 (0.00, 0.00) p=0.062].  87 
By definition sLRI are LRI accompanied by fever (fLRI) and/or wheeze (wLRI). Examining the 88 
individual components showed similar effects of OM85 at decreasing the number of fLRI and wLRI 89 
and the proportion of children experiencing them. However, lack of study power for these 90 
secondary analyses meant that most comparisons did not reach statistical significance 91 
(Supplemental Tables 4 & 5).  92 
Fewer children receiving OM85 had an URI in the first winter season than in the placebo group 93 
(45.8% v 88.5%, p=0.002). The number of URI was also lower in those receiving OM85 than 94 
placebo [median 0.00 (0.00, 1.00) vs 2.00 (1.00, 3.00) p=0.002). There was no difference in the 95 
time to first URI [41.3 (9.4) days vs 50.7 (18.9) days, p=0.69].  96 
The cumulative frequency of sLRI was greater in the placebo group (total 75, median 1.00 (25%, 97 
75% 1.00, 5.00) than in those receiving OM85 [total 58, median 2.00 (25%, 75% 0.00, 3.00)] 98 
(Supplemental Tables 6 &7), Figure 1B, p<0.001). Throughout the study period children in the 99 
placebo group had more days of sLRI [total 838,  median 589 (25%, 75% 428, 749) days] than 100 
those randomized to OM85 [total 656, median 439 (25%, 75% 212, 545) days] (Supplemental 101 
Tables 8 & 9, Figure 1C, p<0.001), and these group differences were greatest in early infancy. 102 
Giving OM85 to infants three to nine months of age was safe and tolerable. Parents opened the 103 
capsule and dissolved the contents in a small amount of liquid (water, breast milk, or formula). The 104 
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most commonly reported adverse events were gastrointestinal disorders, skin conditions, ear 105 
infections and general disorders, with no significant differences between groups (Supplemental 106 
Table 10). 107 
The study did not achieve its primary outcome, in that the overall frequency of sLRI over the first 2 108 
winters in children receiving OM85 and receiving placebo did not differ significantly. However, the 109 
time to first sLRI, was significantly longer for those receiving OM85 than those receiving placebo. 110 
This is encouraging as early sLRI3,4, and in particular reduced time to first sLRI after birth5, 111 
increases the risk of persistent asthma in at-risk children. Moreover, the cumulative frequency of 112 
sLRI, and the number of days with sLRI symptoms, were also significantly lower in those receiving 113 
OM85, suggesting a reduction in the overall inflammatory burden in the lower airways during this 114 
crucial period of early lung growth.  We acknowledge that this proposed mechanism for OM85 is 115 
speculative and requires mechanistic studies. In contrast, while there was a tendency for reduced 116 
overall frequency of LRI in the group receiving OM85, this did not reach statistical significance 117 
during any study period. The implication of these data is that OM85 was more effective at 118 
preventing sLRI than milder LRI.  119 
The effects of OM85 were strongest in the first winter season, with a trend for fewer children in the 120 
OM85 group to have sLRI and URI. There was no evidence of a carry-over protective effect after 121 
treatment had stopped in the first study year.  This suggests that infants and young children may 122 
require treatment all year round to maintain the early benefit of OM85. This lack of carry-over 123 
effect differs from the findings of Razi et al.8. However, they studied older children, not infants, and 124 
the differences in maturational stage of immune development between respective study populations 125 
may play an influence here. In this context we have recently shown that susceptibility to fLRI in 126 
infancy is highest in infants at the lower end of the innate immune development spectrum6.   127 
Despite the study being underpowered, some important lessons have been learned. 1) OM85 128 
appears to be is safe and can be given to infants as young as 3 months of age. 2) OM85 can be used 129 
for primary prevention of sLRI in the high-vulnerability period of infancy, but may not be effective 130 
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months may not be adequate to provide sufficient protection of at-risk infants against sLRI 132 
occurring while off treatment. In this regard, animal studies9 with OM85 suggest that protection 133 
against respiratory viral infection is maximal if treatment is ongoing during the infection period. 134 
Further studies, with greater power, and possibly employing alternative treatment regimens, are 135 
warranted to determine whether OM85 can prevent asthma in at-risk infants and young children.  136 
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Figure 1: Severe Lower Respiratory Illness (sLRI) during the study period. Panel A: Time to 180 
first sLRI, panel B: cumulative frequency of sLRI, panel C: cumulative number of days with sLRI. 181 
Solid line = OM85 group, dashed line = Control group. 182 
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